Siegfried J.W. Ruppert, Ph.D.

Special Counsel
San Francisco,  CA  U.S.A.
Phone415 957 3023

Peer Rating
N/R
 N/R

Client Rating

Printer Friendly VersionEmail this PageDownload to My Outlook ContactsAdd lawyer to My FavoritesCompare this lawyer to other lawyers in your favorites

Experience & Credentials
 

Practice Areas

  • Intellectual Property Law
  • Patents
 
Contact InfoTelephone: 415 957 3023
Fax: 415 358 5920
http://www.duanemorris.com/attorneys/siegfriedjwruppert.html
 
University Ruprecht-Karls University of Heidelberg, B.S., Biological Sciences, 1985; Ruprecht-Karls University of Heidelberg, Ph.D., Biological Sciences, cum laude, 1989
 
Law SchoolUniversity of California, Hastings College of the Law, J.D., 2003
 
Admitted2003, California; Supreme Court of California; U.S. Court of Appeals for the Ninth Circuit; U.S. District Court for the Central District of California; U.S. District Court for the Northern District of California; U.S. Patent and Trademark Office
 
LanguagesGerman
 
Biography

Siegfried J.W. Ruppert, Ph.D., practices in the area of intellectual property law. Dr. Ruppert focuses his practice on patent prosecution, patent interference, patent litigation, patent infringement analysis and opinion work. Dr. Ruppert assists corporate and institutional clients in all areas of life sciences and biotechnology with securing patent rights in the United States and abroad and managing their patent portfolios.

Before entering the legal field, Dr. Ruppert was a scientist at Genentech, Inc., where he and his team identified and characterized novel proteins of therapeutic interest. He was a postdoctoral fellow at both the University of California, Berkeley and the Ruprecht-Karls University of Heidelberg, Germany, where he designed, implemented and managed independent research projects focusing on mammalian gene regulation, transcription factors and cloning of several genes. Dr. Ruppert is an inventor of a number of patents and has co-authored nearly 40 scientific articles in peer-reviewed journals. Dr. Ruppert recently published several articles on biosimilars and presented on legal matters impacting the U.S. biotech industry.

Dr. Ruppert is a 2003 graduate of the University of California, Hastings College of the Law, and a graduate of the Ruprecht-Karls University of Heidelberg (Ph.D., Biological Sciences, cum laude; B.S., Biological Sciences). He is fluent in German.

Representative Matters

Patent Interference and Patent Litigation

· Mophie, Inc. v. Incase Designs Corp., patent interference No. 105,946 (USPTO): Counsel for Mophie, Inc. Prosecuted patent application involving battery packs for mobile devices on behalf of client and succeeded in including all claims and all issued patents of opposing party in interference.

· Assisted in a patent appeal in the Federal Circuit obtaining an affirmation of a trial court victory against collaterally estopped infringement claims regarding magnetically attached auxiliary frames for eyeglasses. Aspex Eyewear Inc. v. Zenni Optical, LLC, Case No. 2012-1318 (Fed. Cir. 2013).

· Aspex Eyewear, Inc. and Contour Optik, Inc. v. Zenni Optical, LLC, 0:09-cv-61468-WJZ (S.D. Fla.), patent infringement: Counsel for Zenni Optical, LLC in a patent infringement action involving magnetic eyewear. Obtained summary judgment in favor of internet retailer against claims that it infringed patents for magnetic eyeglass frames.

· The J. David Gladstone Institutes v. Oregon Health And Science University, patent interference No. 105,686 (USPTO). Supported The J. David Gladstone Institutes in obtaining favorable settlement for client in a patent interference involving HIV-1 technology.

· University of California v. Alza Corporation, patent interference No. 105,332 (USPTO): Obtained judgment of priority for the University of California in an interference involving targeted therapeutic liposomes.

· Luciw v. Chang, patent interference No. 105,291 (USPTO): Counsel for the National Institutes of Health in patent interferences against Novartis/Chiron involving first-generation HIV-1 hybridization assays. Obtained judgment of priority for client.

· Luciw v. Alizon, patent interference No. 105,290 (USPTO): Counsel for the National Institutes of Health in patent interferences against Institut Pasteur involving first-generation HIV-1 hybridization assays.

Patent Prosecution

· Prosecuted U.S. Patent No. 8,523,971, pertaining to multilayer nanofiber filters, on behalf of a Chinese university.

· Prosecuted U.S. Patent No. 8,399,029, pertaining to influenza prevention and treatment compositions, on behalf of a Chinese company.

· Prosecuted U.S. Patent No. 8,349,299, pertaining to a conditioning agent and methods for making hair having a shape memory effect, on behalf of a Chinese university.

· Prosecuted U.S. Patent No. 8,344,007, pertaining to water-soluble polymer-based canthararimides as potentially selective anti-tumor agents, on behalf of a Chinese university.

· Prosecuted U.S. Patent No. 8,338,180, pertaining to methods for treating Lentivirus infections, on behalf of a U.S. research institute.

· Prosecuted U.S. Patent No. 8,329,425, pertaining to methods and systems for the detection of chloramphenicol, on behalf of a Chinese university.

· Prosecuted U.S. Patent No. 8,318,922, pertaining to treatment and prevention of hyperproliferative conditions in humans and antisense oligonucleotide inhibition of human replication-initiation proteins, on behalf of a Chinese university.

· Prosecuted U.S. Patent No. 7,993,647, pertaining to monoclonal antibodies to HIV-1 and methods of using same, on behalf of the National Institutes of Health.

· Prosecuted U.S. Patent No. 7,815,916, pertaining to the cloning and expression of HTLV-III DNA, on behalf of the National Institutes of Health.

· Prosecuted U.S. Patent No. 7,754,861, pertaining to a method for purifying proteins, on behalf of a U.S. biotechnology company.

· Prosecuted U.S. Patent No. 7,723,021, pertaining to methods for treating Lentivirus infections, on behalf of a U.S. research institute.

· Prosecuted U.S. Patent No. 7,645,449, pertaining to sensitizing cells for apoptosis by selectively blocking cytokines, on behalf of a German biotechnology company.

· Prosecuted U.S. Patent No. 6,927,028, pertaining to noninvasive methods for detecting non-host DNA in a host using epigenetic differences between the host and non-host DNA, on behalf of a Chinese university.

Areas of Practice

· Intellectual Property Law

· Patents

· Patent Prosecution

· Patent Interference

· Patent Litigation

· Opinions

· Life Sciences

· Biotechnology

· Mechanical

· Devices

Professional Activities

· Heidelberg Club International

· Heidelberg Alumni U.S.

Experience

· Duane Morris LLP
- Special Counsel, 2010-present

· Townsend and Townsend and Crew LLP
- Associate, 2003-2010

· Flehr Hohbach Test Albritton & Herbert, LLP (now Dorsey & Whitney LLP)
- Patent Agent, 1999-2000

· Genentech, Inc.
- Scientist, 1994-1997

Selected Publications

· Co-author, "Virginia Enacts the First State Law Regulating Interchangeable Biosimilar Products," Duane Morris Alert, March 28, 2013

· Co-author, "Path for Generics Open in Biotech," The Recorder, March 5, 2012

· "FDA's Draft Guidance on "Biosimilar" Pathway Leaves Key Questions on Specific Clinical Data Requirements and Interchangeability Unanswered," GenericsWeb InnSight, February 2012

· Co-author, "FDA Issues Draft Guidance Documents to Implement the Biologics Price Competition and Innovation Act of 2009," Duane Morris Alert, February 13, 2012

· Author, "FDA Sends Prescription Drug User Fee Act V to Congress for Reauthorization," Duane Morris Alert, January 23, 2012

· Co-author, "Forecasting Forthcoming 'Biosimilar' Drug Regulations," The Recorder, August 30, 2011

· Author, "A Look Ahead: FDA's Approach to Biosimilars - Totality of the Evidence and Risk-Based," GenericsWeb newsletter InnSight, August 2011

· Author, "Biosimilars - Faster Development and Approval?," GenericsWeb newsletter InnSight, March 2011

· Co-author, "Rb interacts with TAFII250/TFIID through multiple domains distinct from E2F and viral oncoprotein binding regions," Oncogene 15, 385-392 (1997)

· Co-author, "Apo-2 ligand activates apoptosis in stimulated peripheral blood T cells," Current Biology 6, 750-752 (1996)

· Co-author, "Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family," J. Biol. Chem 271, 12687-12690 (1996)

· Co-author, "New type of POU domain in germ line-specific protein Oct-4," Nature 344, 435-439 (1990)

· Co-author, "TAFII250 is a bipartite protein kinase that phosphorylates the basal transcription factor RAP74," Cell 84, 781-790 (1996)

· Co-author, "Human TAFII250 interacts with RAP74: implications for RNA polymerase II initiation," Genes & Dev. 9, 2747-2755 (1995)

· Co-author, "Two genetically defined trans-acting loci coordinately regulate overlapping sets of liver-specific genes," Cell 61, 895-904 (1990)

· Co-author, "The retinoblastoma-susceptibility gene product binds directly to the human TATA-binding protein-associated factor TAFII250," Proc. Natl. Acad. Sci. USA 92, 3115-3119 (1995)

· Co-author, "Multiple regions of TBP participate in the response to transcriptional activators in vivo," Genes & Dev. 8, 2756-2769 (1994)

· Co-author, "Rescue of mice homozygous for lethal albino deletions: Implications for an animal model for human liver disease tyrosinaemia type 1," Genes & Dev. 7 (12a), 2285-2297 (1993)

· Co-author, "Isolation of the gene for murine glucose-6-phosphatase, the enzyme deficient in glycogen storage disease Type 1A," J. Biol. Chem. 268, 21482-21485 (1993)

· Co-author, "Cloning and expression of Drosophila TAFII60 and human TAFII70 reveals conserved interactions with other subunits of TFIID," EMBO Journal 12 (13), 5303-5309 (1993)

· Co-author, "The mouse tyrosinase gene : Pigment cell-specific gene expression in transgenic mice," Pharmacology of the Skin, Vol. 5, From Molecular Biology to Therapeutics, B.A. Bernhard and B. Shroot (eds), Karger, Basel, 57-62 (1993)

· Co-author, "Multiple effects on liver-specific gene expression in albino lethal mice caused by deficiency of an enzyme in tyrosine metabolism," Journal of Cell Science Supplement 16, 117-122 (1992)

· Co-author, "An amphicrine pancreatic cell line: AR42J cells combine exocrine and neuroendocrine properties," European Journal of Cell Biology 59, 80-91 (1992)

· Co-author, "Molecular characterization of the mouse tyrosinase gene: Pigment cell-specific expression in transgenic mice," Pigment Cell Research 5, 295-29 (1992)

· Co-author, "Deficiency of an enzyme of tyrosine metabolism underlies altered gene expression in newborn liver of lethal albino mice," Genes & Dev. 6, 1430-1443 (1992)

· Co-author, "Chromosome jumping from flanking markers defines the minimal region for alf/hsdr-1 within the albino-deletion complex," Genomics 14, 288-297 (1992)

· Co-author, "Physical mapping of the albino-deletion complex in the mouse to localize alf/hsdr-1, a locus required for neonatal survival," Genomics 14, 275-287 (1992)

· Co-author, "The mouse CREB (cAMP responsive element binding protein) gene: structure, promoter analysis, and chromosomal localization," Genomics 13 (4), 974-982 (1992)

· Co-author, "Multiple mRNA isoforms of the transcription activator protein CREB: generation by alternative splicing and specific expression in spermatocytes," EMBO Journal 11, 1503-1512 (1992)

· Co-author, "The albino-deletion complex of the mouse: molecular mapping of deletion breakpoints that define regions necessary for development of the embryonic and extraebryonic ectoderm," Genetics 129, 825-832 (1991)

· Co-author, "Tyrosinase as a marker for transgenic mice," Nucleic Acids Res. 19, 958 (1991)

· Co-author, "The mouse tyrosinase promoter is sufficient for expression in melanocytes and in the pigmented epithelium of the retina," Proc. Natl. Acad. Sci. USA 88, 3777-3781 (1991)

· Co-author, "Isolation and characterization of mouse hepatocyte lines carrying a lethal albino deletion," J. Biol. Chem. 266, 5716-5722 (1991)

· Co-author, "Molecular mapping of albino deletions associated with early embryonic lethality in the mouse," Genomics 9, 162-169 (1991)

· Co-author, "Hormonal and liver-specific control of expression of the tyrosine aminotransferase gene," Molecular Aspects of Cellular Regulation, Vol. 6, The Hormonal Control Regulation of Gene Transcription. p 223-234 (1991)

· Co-author, "Rescue of the albino phenotype by introduction of a functional tyrosinase gene into mice," EMBO Journal 9, 2819-2826 (1990)

· Co-author, "Structure, mapping and expression of a growth factor inducible gene encoding a putative nuclear hormonal binding receptor," EMBO Journal 11, 3327-3335 (1989)

· Co-author, "The albino perinatal lethal deletion: Identification of affected mRNAs and mapping of the locus by pulsed-field gel electrophoresis," NATO ASI Series, Vol. H34. Vectors as Tools for the Study of Normal and Abnormal Growth and Differentiation, pp 47-62 (1989)

· Co-author, "A cloned octamer transcription factor stimulates transcription from lymphoid-specific promoters in non-B cells," Nature 336, 544-551 (1988)

· Co-author, "Functional analysis of alternatively spliced tyrosinase gene transcripts," EMBO Journal 9, 2723-2730 (1988)

· Co-author, "Multiple transcripts of the mouse tyrosinase gene are generated by alternative splicing," EMBO Journal 9, 2715-2722 (1988)

· Co-author, "Genomic footprinting reveals cell type-specific DNA binding of ubiquitous factors," Cell 51, 435-443 (1987)

· Co-author, "Isolation, characterization and chromosomal mapping of the mouse tyrosine aminotransferase gene," J. Mol. Biol. 184, 367-373 (1985)

· Co-author, "Recent gene conversion involving bovine vasopressin and oxytocin precursor genes suggested by nucleotide sequence," Nature 308, 554-557 (1984)

· Co-author, "Deduced amino acid sequence from the bovine oxytocin-neurophysin I precursor cDNA," Nature 302, 342-344 (1983)

Selected Speaking Engagements

· "A Perspective Of The U.S. Biotech Industry After Mayo And Myriad," a presentation for the Technology Park in Heidelberg, Germany, August 2013

· " Mayo vs. Prometheus-Alarm In The Biotech Industry," a presentation for the Technology Park in Heidelberg, Germany, May 2012

· "The U.S. Biosimilar Pathway-Legal & Regulatory Considerations," A presentation for LES AK Life Science, Munich, Germany, May 2012

· " Mayo-Alarm in Biotech," CLE Presentation, Duane Morris, San Francisco, U.S.A., April 2012

· " Mayo-Alarm in Biotech," a presentation for the Massachusetts Institutes of Technology, Boston, U.S.A., March 2012

· "Central Valley Business Incubator Protecting Your Ideas-Patents," a presentation to CART in Fresno, U.S.A., December 2011

· "Approval Process For Biosimilar Biological Products," CLE Presentation, 2011

 
ISLN917502871
 
Profile Visibility
#1,213 in weekly profile views out of 21,607 lawyers in San Francisco, California
#111,830 in weekly profile views out of 1,616,736 total lawyers Overall

Office Information

Siegfried J.W. Ruppert, Ph.D.

One Market Plaza, Suite 2200
San FranciscoCA 94105-1127




Loading...
 

Professional Networking for Legal Professionals Only

Quickly and easily expand your professional
network - join the premier global network for legal professionals only. It's powered by the
Martindale-Hubbell database - over 1,000,000 lawyers strong.
Join Now